Results 201 to 210 of about 89,179 (297)

Hemocompatibility Outcomes After Aspirin Withdrawal in Long‐Term HeartMate 3 Left Ventricular Assist Device Patients on Vitamin K Antagonists

open access: yesArtificial Organs, EarlyView.
Aspirin discontinuation in long‐term, stable Heart Mate 3 LVAD patients maintained on Vitamin K antagonists did not increase hemocompatibility‐related adverse events. These findings support the safety of simplified antithrombotic therapy and extend randomized evidence for aspirin avoidance to the long‐term management of Heart Mate 3 recipients ...
Melanie Arnreiter   +8 more
wiley   +1 more source

The Impact of Obesity on Durable Left Ventricular Assist Device Implantation: A Systematic Review and Meta‐Analysis

open access: yesArtificial Organs, EarlyView.
14 100 LVAD patients across 21 studies were analyzed. Findings indicated that obese LVAD recipients had lower short‐term mortality and higher risk of infection, thrombosis and right heart failure. There was no difference in long‐term survival between obese and non‐obese patients.
Hugh Jacobs   +11 more
wiley   +1 more source

Optimizing Prolonged (6 h) Normothermic Machine Perfusion of Donor Kidneys (PROPER Study)

open access: yesArtificial Organs, EarlyView.
Prolonged ex situ normothermic machine perfusion of donor kidneys up to 6 h is feasible, maintaining viability and histological integrity. Key protocol optimizations include fresh red blood cells, albumin supplementation, and urine recirculation—laying the groundwork for assessment and potential pretransplant interventions in future clinical trials ...
Asel S. Arykbaeva   +14 more
wiley   +1 more source

Driveline Infections Among Patients Supported With Left Ventricular Assist Devices: A Single Center Sixteen‐Year Longitudinal Profile

open access: yesArtificial Organs, EarlyView.
Our study of 1026 LVAD implants revealed HeartWare had lower driveline infection rates than other LVAD types. In addition, severe diabetes was associated with higher risk, while older age and coronary artery disease were linked to a lower risk of driveline infections.
Anh Nguyen   +6 more
wiley   +1 more source

Hemocompatibility and Long‐Term Outcomes in HeartWare Versus HeartMate II Versus HeartMate 3: Multicenter Real‐World Cohort

open access: yesArtificial Organs, EarlyView.
Multicenter real‐world cohort (n = 327) comparing LVADs: HeartMate 3 (HM3), HeartMate II (HMII), and HeartWare (HVAD). HM3 showed superior long‐term survival versus legacy devices, driven by fewer hemocompatibility‐related adverse events, especially pump thrombosis and ischemic stroke, while major bleeding was similar across devices.
Hamza H. H. Ben Nasir   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy